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Abstract: The reversal of low-molecular-weight heparin (LMWH) and the management of
bleeding patients on LMWH remain highly challenging. Even if LMWH is very extensively
administered in the prophylaxis and treatment of venous thrombosis, specific antidotes are
lacking, and reversal strategies have very weak grade of evidences on clinical effectiveness.
We here describe a reversal strategy with protamine and FVIIa in a patient presenting with
hemorrhagic shock and cardiocirculatory arrest.
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Introduction
The reversal of low-molecular-weight heparin (LMWH) and the management of
bleeding patients on LMWH remain highly challenging.1 Even if LMWHs are
very extensively administeredadministrated in the prophylaxis and treatment of
venous thrombosis, specific antidotes are lacking, and reversal strategies have
very weak grade of evidences on clinical effectiveness. Protamine is recom-
mended for the reversal of LMWH but it is able to partially revert the LMWH
anti–Xa activity.2–4 Furthermore, protamine efficacy appears to be time-dependent,
rendering it highly challenging when treating bleeding patients on LMWH.
Protamine-alone strategies to neutralize LMWH are indeed unreliable, especially
in life-threating bleeding.
Guidelines did not include or suggest other antidotes or procoagulants able to
cooperate with protamine in such scenario. Few reports have been published describ-
ing the administration of FVIIa, which is not indicated for this clinical condition.5
The management of life-threating bleeding upon/or during LMWH remains chal-
lenging andwithout precise indication from the guidelines. In the following case report,
we will discuss LMWH reversal for severe bleeding in a lymphoma patient.
Case Report
An 86-year-old patient was admitted to our Division of Internal Medicine –
Hematology – due to the diagnosis of Non-Hodgkin Lymphoma, mantle cell type.
Presentation included stage IV disease with lung involvement, splenomegaly, lympha-
denomegaly and clonal lymphocytosis at the peripheral blood. The patient was suffer-
ing from chronic atrial fibrillation and was under chronic anticoagulation with
vitamin K antagonists. During hospitalization, VKA was substituted with LMWH
therapy to easily perform diagnostic biopsies (bone marrow) and invasive procedures
upon transitorily interruption of the LMWH anticoagulation. Due to the need for
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adequate venous access, we disposed for the placement of
a central venous catheter, with ultrasound guidance at the
subclavian vein. This procedure was complicated by the
development of a pneumothorax which required drainage.
The day after drainage removal, LMWH (enoxaparin) was
administered at a dose of 100 U/Kg twice daily. Forty-eight
hours laterthe patient presented with severe hypotension and
signs of peripheral hypoperfusion. Lactic acid was elevated
(11 mMol/L). A thorax Computer Tomography (CT) scan
with contrast was performed revealing the occurrence of
severe bleeding on the previous site of pneumothorax. No
variation in the clotting times was observed and no signifi-
cant changes in kidney and liver function were documented
before this acute event. While attempting to dispose for
a novel thoracic drainage, the patient's clinical conditions
were dramatically worsening with the development of cardi-
ocirculatory arrest, due to pulseless electrical activity (PEA).
Resuscitation was started accordingly following the guide-
lines for PEA.
It became clear that the only way to save the patient's life
would be to reverse the bleeding, the drainage and the blood
transfusion to achieve an adequate perfusion. During cardio-
pulmonary resuscitation (CPR) – although LMWH was
administered around 8 hrs earlier – we decided to administer
1 mg protamine followed by 90 μg/kg of Factor VIIa.
Simultaneously, a blood transfusion was started. In the
absence of clear guidelines, we used protamine sulfate to
potentially reverse those LMWH molecules which were still
circulating and complexed with anti-thrombin. Due to the
partial reversal potential of protamine and the presence of
cardiac arrest, we realized that this strategy would not have
been sufficient for a rapid and strong reversal. Thus, we
decided to rapidly administer Factor VIIa hoping to trigger
coagulation, maximizing the activation of residual factor-X.
At the end of this combinatorial therapy, and still during
CPR, the thoracic drainage was positioned. Progressively,
signs of perfusions were observed and CPR was stopped.
The patient was subsequently transferred to the Intensive
Unit Care where he also received a plasma transfusion
(15 mg/kg). Two hours later, the patient was transferred to
the operating room and a thoracoscopy was performed.
A clear bleeding site was observed close to the previous
drainage site and was treated accordingly. Recovery was
complete and in two days the patient was transferred back
to our Division. No neurological defects were observed, and
no sign of deep vein thrombosis and/or pulmonary embolism
were detected. However, transient kidney failure was
observed, but without the need for renal dialysis kidney
function subsequently recovered. Subsequently, mantle cell
lymphoma was treated with a rituximab-chlorambucil-
prednisone regiment. Three months later the patient was
well and continued a monthly chemotherapy regimen as
an outpatient.
Conclusions
This case report describes a hemorrhagic shock evolving
into cardiac arrest in a patient receiving LMWH. In such
a dramatic clinical scenario, our bleeding reversal strategy
included the administration of protamine and FVIIa, allow-
ing us to achieve a complete hemostasis without side
effects. It is worth noting that the dosage of protamine
was very low, considering the time of LMWH administra-
tion, and that plasma was infused when the patient was
already stable. Therefore, FVIIa appeared the most effec-
tive strategy to promote LMWH reversal. This case report
may lead to the following comments:
(i) In older patients with comorbidities, such as lym-
phomas, the indication of every invasive proce-
dures should be carefully reviewed. The dramatic
story described above may be prevented with the
use of a peripherally inserted central catheter
(PICC) despite the placement of a central vein
catheter.
(ii) The management of major bleeding in patients on
LMWH remains challenging. This case report
questions whether protamine alone is effective
enough to attempt LMWH reversal.
(iii) Lastly, we may provide some insight on the safety
of the combinatorial therapy, protamine and FVIIa.
In this life-threatening situation, FVIIa should acti-
vate FX, allowing us to bypass the residual inhibi-
tion by LMWH. Interestingly, the association
protamine and FVIIa did not promote any throm-
botic complications in our patient, even when pro-
tamine was used at low dose.
Ethical Disclosure
The case report was described upon written informed
consent of the patient’s son and daughter to have the
case details published. The patient passed away before
publication for causes independent of the case report.
Institutional approval was not required for publication.
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